BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

Información del proyecto

REMEDi4ALL

Identificador del acuerdo de subvención: 101057442

DOI

10.3030/101057442

Fecha de la firma de la CE 19 Mayo 2022

Fecha de inicio 1 Septiembre 2022

Fecha de finalización 31 Agosto 2027

Financiado con arreglo a

• Health

Coste total

€ 22 561 532,00

Aportación de la UE

€ 22 561 532,00

Coordinado por

EATRIS ERIC
Netherlands

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (6)

Report on AI tools and data resource

Report on existing AI tools and data resources carefully tested, ranked and classified for various repurposing applications.

Training landscape map

Report summarising existing information training and support in DR with publicfacing signposting to existing repurposing resources and trainings

Report on establishment of the Funders network

Documentation of commitment of funders that are motivated to join the Repurposing Funders Network, including Charter.

Report on the strategy and roadmap for collaboration with other synergies

This report will provide a guide of synergies with other projects and networks to be implemented during the project the methodological framework process and sources for the identification of projects with which to build synergies

Report on the 1st Annual Conference

Report on the 1st Annual Conference describing program highlights, attendees, interactions with key stakeholders and suggestions for agenda and organisation of next conference.

Report on services, expertise, barriers in the clinical development

Report describing the mapping of the clinical drug repruposing landscape identification of barriers gap analysis and blueprint report focusing on the clinical development

Publicaciones

Peer reviewed articles (16)

Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia

Autores: Adnan Awad, Shady; Dufva, Olli; Klievink, Jay; Karjalainen, Ella; Ianevski, Aleksandr; Pietarinen, Paavo; Kim, Daehong; Potdar, Swapnil; Wolf, Maija; Lotfi, Kourosh; Aittokallio, Tero; Wennerberg, Krister; Porkka, Kimmo; Mustjoki, Satu
Publicado en: Cell Reports Medicine, 2024, ISSN 2666-3791
Editor: Elsevier
DOI: 10.1016/J.XCRM.2024.101521

Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta

Autores: Paul Arundel; Nick Bishop
Publicado en: Calcified Tissue International, 2024, ISSN 1432-0827
Editor: Springer Nature
DOI: 10.1007/S00223-024-01202-7

Robust scoring of selective drug responses for patient-tailored therapy selection

Autores: Yingjia Chen; Liye He; Aleksandr Ianevski; Pilar Ayuda-Durán; Swapnil Potdar; Jani Saarela; Juho J. Miettinen; Sari Kytölä; Susanna Miettinen; Mikko Manninen; Caroline A. Heckman; Jorrit M. Enserink; Krister Wennerberg; Tero Aittokallio
Publicado en: Nature Protocols, 2023, ISSN 1750-2799
Editor: Nature Portfolio
DOI: 10.1038/S41596-023-00903-X

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol

Autores: Alfredo Budillon, Alessandra Leone, Eugenia Passaro, Lucrezia Silvestro, Francesca Foschini, Federica Iannelli, Maria Serena Roca, Marina Macchini, Francesca Bruzzese, Maria Laura Garcia Bermejo, Mercedes Rodriguez Garrote, Giampaolo Tortora, Michele Mile
Publicado en: BMC Cancer, 2024, ISSN 1471-2407
Editor: BioMed Central
DOI: 10.1186/S12885-024-12936-W

Improved Detection of Drug-Induced Liver Injury by Integrating Predicted<i>in vivo</i>and<i>in vitro</i>Data

Autores: Srijit Seal; Dominic P. Williams; Layla Hosseini-Gerami; Manas Mahale; Anne E. Carpenter; Ola Spjuth; Andreas Bender
Publicado en: Chemical Research in Toxicology, 2024, ISSN 1520-5010
Editor: American Chemical Society
DOI: 10.1021/ACS.CHEMRESTOX.4C00015

Nature Communications

Autores: Aleksandr Ianevski; Kristen Nader; Kyriaki Driva; Wojciech Senkowski; Daria Bulanova; Lidia Moyano-Galceran; Tanja Ruokoranta; Heikki Kuusanmäki; Nemo Ikonen; Philipp Sergeev; Markus Vähä-Koskela; Anil K. Giri; Anna Vähärautio; Mika Kontro; Kimmo Porkka; Esa Pitkänen; Caroline A. Heckman; Krister Wennerberg; Tero Aittokallio
Publicado en: Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones, 2024, ISSN 2041-1723
Editor: Springer Nature
DOI: 10.1038/S41467-024-52980-5

RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies

Autores: Aleksandr Ianevski; Aleksandr Kushnir; Kristen Nader; Mitro Miihkinen; Henri Xhaard; Tero Aittokallio; Ziaurrehman Tanoli
Publicado en: Briefings in Bioinformatics, 2024, ISSN 1477-4054
Editor: Oxford University Press
DOI: 10.1093/BIB/BBAE328

Cell Painting: a decade of discovery and innovation in cellular imaging

Autores: Seal, Srijit; Trapotsi, Maria-Anna; Spjuth, Ola; Singh, Shantanu; Carreras-Puigvert, Jordi; Greene, Nigel; Bender, Andreas; Carpenter, Anne E
Publicado en: Nature Methods, 2024, ISSN 1548-7105
Editor: Nature Portfolio
DOI: 10.17863/CAM.112378

Artificial intelligence for high content imaging in drug discovery

Autores: Jordi Carreras-Puigvert; Ola Spjuth
Publicado en: Current Opinion in Structural Biology, 2024, ISSN 1879-033X
Editor: Elsevier
DOI: 10.1016/J.SBI.2024.102842

HPR155 Drug Repurposing: Policy Barriers to Using Existing Pharmaceuticals in New Indications: Results of a Systematic Literature Review

Autores: Z Petykó, D Hosszú, M Csanádi, GD Obeng, D Ameyaw, K Gyöngyösi, HG van der Meer, P Pantziarka, Z Kalo, A Inotai
Publicado en: Value in Health, Edición 27, 2024, ISSN 1098-3015
Editor: Elsevier BV
DOI: 10.1016/J.JVAL.2024.10.1581

From pixels to phenotypes: Integrating image-based profiling with cell health data as BioMorph features improves interpretability

Autores: Srijit Seal; Jordi Carreras-Puigvert; Shantanu Singh; Anne E. Carpenter; Ola Spjuth; Andreas Bender
Publicado en: Molecular Biology of the Cell, 2024, ISSN 1939-4586
Editor: American Society for Cell Biology
DOI: 10.1091/MBC.E23-08-0298

Attention-based approach to predict drug-target interactions across seven target superfamilies

Autores: Aron Schulman; Juho Rousu; Tero Aittokallio; Ziaurrehman Tanoli
Publicado en: Bioinformatics, 2024, ISSN 1367-4811
Editor: Oxford University Press
DOI: 10.1093/BIOINFORMATICS/BTAE496

Drug repurposing in Rett and Rett-like syndromes: a promising yet underrated opportunity?

Autores: Claudia Fuchs; Peter A. C. ‘t Hoen; Annelieke R. Müller; Annelieke R. Müller; Annelieke R. Müller; Friederike Ehrhart; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek; Clara D. M. Van Karnebeek
Publicado en: Frontiers in Medicine, 2024, ISSN 2296-858X
Editor: Frontiers Media
DOI: 10.3389/FMED.2024.1425038

Exploring SureChEMBL from a drug discovery perspective

Autores: Yojana Gadiya; Simran Shetty; Martin Hofmann-Apitius; Philip Gribbon; Andrea Zaliani
Publicado en: Nature Scientific Data, 2024, ISSN 2052-4463
Editor: Nature Portfolio
DOI: 10.1038/S41597-024-03371-4

Drug repurposing for rare: progress and opportunities for the rare disease community

Autores: Anneliene Hechtelt Jonker; Anneliene Hechtelt Jonker; Daniel O’Connor; Daniel O’Connor; Maria Cavaller-Bellaubi; Maria Cavaller-Bellaubi; Christine Fetro; Christine Fetro; Maria Gogou; Maria Gogou; Peter A. C. ’T Hoen; Peter A. C. ’T Hoen; Martin de Kort; Martin de Kort; Heather Stone; Heather Stone; Nivedita Valentine; Nivedita Valentine; Anna Maria Gerdina Pasmooij; Anna Maria Gerdina Pasmooij
Publicado en: Frontiers in Medicine, 2024, ISSN 2296-858X
Editor: Frontiers Media
DOI: 10.3389/FMED.2024.1352803

Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank

Autores: Srijit Seal; Ola Spjuth; Layla Hosseini-Gerami; Miguel García-Ortegón; Shantanu Singh; Andreas Bender; Anne E. Carpenter
Publicado en: Journal of Chemical Information and Modeling, 2024, ISSN 1520-5142
Editor: American Chemical Society
DOI: 10.1021/ACS.JCIM.3C01834

Other (1)

REMEDi4ALL - Standard Operating Guideline - Fair Data Assessment

Autores: Gadiya, Yojana; Zaliani, Andrea
Publicado en: Zenodo, 2025
Editor: Zenodo
DOI: 10.5281/ZENODO.14605175